Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED STATES: Federal Appeals Court Blocks Teva from Selling


New York Times (09.08.07) - Monday, September 10, 2007

On Friday, Teva Pharmaceuticals announced that a federal appeals court had temporarily enjoined the firm from selling the generic drug famciclovir, which is used to treat herpes, cold sores, and shingles. The injunction will remain in effect until an emergency motion for a stay filed by Novartis, which contends it holds patents for Famvir (famciclovir) valid until 2015, can be considered. A Federal District Court in Newark had previously denied Novartis a preliminary injunction, allowing Teva to introduce the generic to US consumers. The two companies have been in patent infringement litigation since 2005.


Copyright © 2007 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in September 10, 2007. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.